Visible changes in body composition
Inform your doctor about all medications, supplements, and herbal products you are using to avoid potential interactions
Option Cagrilintide Evidence for the added compound Human Phase 2 data alone and Phase 3 data with semaglutide Evidence for the retatrutide combination None identified Option Tesamorelin Evidence for the added compound Randomized trials and an FDA-approved narrow indication Evidence for the retatrutide combination None identified Option CJC-1295 + ipamorelin Evidence for the added compound Small human studies showing GH or IGF-1 response Evidence for the retatrutide combination None identified Option MOTS-C Evidence for the added compound Human observational biology plus mostly preclinical treatment research Evidence for the retatrutide combination None identified This ranking describes research depth

Patients who have a lower cardiovascular risk should consider SGLT-2 inhibitors or GLP-1 agonists based on other established benefits such as weight control (moderate net weight loss for GLP-1 agonists and small weight loss for SGLT-2 inhibitors) against risks of genital infections (SGLT-2 inhibitors) or gastrointestinal disturbances (GLP-1 agonists)
(Even prior to this use, doctors could prescribe the diabetes versions drug off label for weight loss.) I wrote about this more here
With semaglutide and tirzepatides associations to eye disorders making headlines in recent days, GPs are warned that patients may present in their clinics with heightened safety concerns